Clinical trials
EBV clinical trials
Below are recruiting ebv clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07019870Recruiting
Screening for early diagnosis of nose cancer
This trial offers free screening to find nose cancer (nasopharyngeal carcinoma or NPC) early, before symptoms start. It is for people with a family history of NPC who may be at higher risk.
SingaporeAges 35–60 - NCT06702072Recruiting
Oxygen use after lung valve treatment
Researchers want to see if a bronchoscopic lung volume reduction procedure with Zephyr valves changes how much oxygen your body uses during simple tasks. You may be eligible if you are scheduled for this valve treatment and do not rely on constant oxygen for daily activities.
GroningenAges Any age - NCT06689397Enrolling by invitation
Study of Epstein-Barr virus-related pink eye
This trial is studying a specific type of eye infection (pink eye) caused by the Epstein-Barr virus. It aims to better understand the condition and may help guide treatment for people with these symptoms.
LondonAges 16 years+ - NCT06682442Recruiting
Chemotherapy-guided radiation for EBV-related nasopharyngeal cancer
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
San Francisco, CaliforniaAges 18 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for lymphoma that returns after an organ transplant
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
St Louis, MissouriAges 18 years+ - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06069830Recruiting
PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT05587543RecruitingEarly Phase 1
Test of EBV CAR-T or TCR-T cells for nasopharyngeal cancer
This early-phase study tests personalized immune cells (EBV CAR-T or TCR-T) to treat nasopharyngeal cancer that has returned or spread. It aims to help the immune system find and attack the cancer after other treatments have not worked.
ShanghaiAges 18–75 - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT04308278RecruitingPhase 4
Homeopathic treatment for Epstein-Barr virus fatigue
This study tests a homeopathic treatment (2LEBV® and 2LXFS®) for people with Epstein-Barr virus infection who experience long-lasting fatigue and other symptoms. It aims to see if this treatment helps reduce fatigue and improve overall well-being.
Heule, KortrijkAges 12 years+ - NCT04013802RecruitingPhase 1
Multivirus T-cell treatment for EBV, CMV, adenovirus, and BK after transplant
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
Houston, TexasAges Any age - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ebv?
- Yes. Clin2 currently lists 64 recruiting ebv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ebv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ebv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.